Date: 2011-01-25
Type of information: Licensing agreement
Compound: BioPrint® (pharmacology and ADME database)
Company: Cerep (France) Shire (UK-USA)
Therapeutic area:
Type agreement: Licensing
Action mechanism: database composed of three main data sets: chemical descriptors (structures and chemical information, 2D and 3D descriptors), in vitro profi les and in vivo effects of tested compound.
Disease:
Details: Cerep has announced the signature of an evaluation license with Shire on BioPrint®. The agreement gives Shire access to the BioPrint® database and related pharmaco-informatics tools. In addition, Cerep will generate new BioPrint® data on Shire compounds for Shire’s exclusive use. Shire and Cerep will also collaborate on further development of BioPrint® and related pharmaco-informatics tools aimed at predicting adverse drug reactions as early as possible in pre-clinical research.
Financial terms: Cerep will receive an annual license fee and payments for the generation of new BioPrint® data.
Latest news:
